KRAS and cancer: To assist cancer cells overcome oxidative stress barriers during carcinogenesis, mutations in KEAP1 trigger the nuclear factor erythroid‐related factor 2 (NRF2) antioxidant program and work in tandem with mutant KRAS to drive the development of lung adenocarcinoma (LUAD) [103, 104, 105, 106, 107, 108].